drugset / Trial / NCT00947882
A Trial of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)
RandomizedParallel-groupTriple-blindTreatment
Summary
A dose-finding, multi-centre, double-blind, randomised, parallel, placebo-controlled trial to investigate efficacy and safety of degarelix in men with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)
Timeline
- Start
- 2009-08
- Primary completion
- 2011-03
- Completion
- 2011-06
Outcome
Missed primary endpoint
registry analysis (superiority or other test); Placebo vs Degarelix 30 mg; p = 0.0911 NCT00947882 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Degarelix | Other / unclassified | 10 mg | — |
| Subject | Degarelix | Other / unclassified | 20 mg | — |
| Subject | Degarelix | Other / unclassified | 30 mg | — |
Indications
No indication recorded.